An interventional study of Intrathecal catheter connected to an implantable pump and Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections in Pancreatic Cancer Pain, Intrathecal Analgesic and Intrathecal Administration of the Drug, sponsored by Clinique Bizet. Not yet recruiting at 3 sites in France. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Clinique Bizet · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 234 studies in Pancreatic Neoplasms with a site in France — 52 open to participants now, 74 under way, 11 of them phase 3. Pancreatic Neoplasms · France.
Among the 234 studies in Pancreatic Neoplasms with a site in France, this one is the 146th largest by planned enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2026, is one of 44 with no phase, reaches primary completion later than 28 of the 73 other live ones, and was the 232nd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →52 of the 234 studies in Pancreatic Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Bristol-Myers Squibb · Sites in France, United States, Belgium and 10 more countries
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Incyte Corporation · Sites in France, United States, Australia and 19 more countries
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
234 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 72 · Phase 3 49 · Phase 4 2
First in 1997; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 150 across the 181 interventional studies, 200 across the 45 observational. Of the 136 that completed or were terminated, 41 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 234 have an industry lead sponsor. The 10 most frequent:
Clinique Bizet is the lead sponsor of 16 studies on the registry; 11 are open to participants now.
Clinique Bizet has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies in Pancreatic Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03915678Institut BergoniéAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | 2026-12 |
| NCT06071507IRCCS San RaffaeleManagement of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy | 2026-12 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT06755359Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer | 2027-01 |
| NCT05143970Institut Paoli-CalmettesA Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 234 studies in Pancreatic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to assess the effectiveness of intratracheal analgesia on pain intensity in cancer patients, from the start of treatment up to 3 months. It will also investigate the safety of this technique. The main questions it seeks to answer are as follows:
What is the impact on the use of opioid analgesics, and can this be measured? What is the quality of life? What is the quality of sleep, and can this be assessed? How does the patient's weight change? Is the patient satisfied? What is the patient's overall survival?
The researchers will assess the equivalent daily dose of morphine (mg/day) between enrolment and follow-up visits, as well as the number of patients requiring an escalation of analgesic treatment. Overall quality of life score measured using the ESAS questionnaire between enrolment and follow-up visits; satisfaction assessed using a numerical satisfaction scale (0-10); sleep quality assessed using the ISI questionnaire; and the tolerability and safety of the technique assessed by monitoring adverse events.
Eligible participants:
Following implantation of the intrathecal pump, participants will have scheduled consultations at day 30, then at 3, 6, 9 and 12 months, with questionnaires to be completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject aged over 20 years
Exclusion Criteria:
Patients under the age of 20.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of the medicine via an intrathecal catheter connected to an implantable pump
Device: Intrathecal catheter connected to an implantable pump · Drug: Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections
Epidural puncture (AL injection), followed by a lumbar puncture and collection of cerebrospinal fluid. Positioning of the catheter behind the spinal cord at the desired metameric level for the pancreas (T5-T7), and positioning of the pump in the flank or buttock.
Medications are administered via an intrathecal catheter connected to an implantable pump or via periodic injections; the patient is admitted to hospital with morphine (IV, PO, transdermal) discontinued on entry to the unit (the same applies to methadone). Depending on the condition of the patient's abdominal skin (stoma, multiple injections, etc.) and any foreseeable technical difficulties during MRI scanning (in the left or right lateral positions), the procedure is performed under fluoroscopy, with appropriate antibiotic prophylaxis, under local anaesthesia, epidural anaesthesia and light sedation. Product used, dosage and frequency: Opioids: μ and δ receptors: Morphine sulphate: 50 mg/ml Ca++ channels: ziconotide: initial dose 0.5 µg/day Sodium channels: 1% ropivacaine As with a patient-controlled analgesia (PCA) system: Continuous infusion + bolus or sequential boluses Patient education on the use of the pump during their hospital stay.
Change in Edmonton Symptom Assessment System (ESAS) - Pain Subscore
Change in pain intensity score measured by the ESAS subscale from baseline to follow-up visits. Unit of Measure: Score on a scale (0 to 10) Scale Range (Minimum and Maximum Values): 0 to 10 Direction of Scores: Higher scores mean a worse outcome (greater pain intensity).
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Change in Edmonton Symptom Assessment System (ESAS) Overall Quality of Life Score
Change in overall score as measured by the Edmonton Symptom Assessment System (ESAS) from baseline to follow-up visits. Unit of Measure: Score on a scale (ESAS Score) Scale Range (Minimum and Maximum Values): 0 to 10 Direction of Scores: Higher scores mean a worse outcome (greater pain intensity).
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Proportion of Patients Requiring Pain Treatment Escalation
Number of patients requiring an increase or escalation in pain management treatment during follow-up. Unit of Measure: Number of participants (or Percentage)
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Change in Daily Morphine Equivalent Dose (MED)
Change in daily opioid dose from baseline to follow-up visits. Unit of Measure: mg/day
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Change in Sleep Quality Score Insomnia Severity Index (ISI)
Change in insomnia severity measured by the Insomnia Severity Index (ISI) questionnaire from baseline to follow-up visits. Scale Range (Minimum and Maximum Values): 0 to 28 (Derived from summing the 7 individual items, each scored on a 0 to 4 scale evaluating sleep onset, maintenance, early morning awakening, satisfaction, daytime interference, noticeability, and distress) Direction of Scores: Higher score 4 means a worse outcome (greater insomnia severity and impaired quality of life) Unit of Measure: Score on a scale (ISI Score)
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Change in Body Weight
Change in body weight from baseline to follow-up visits. Unit of Measure: Kilograms (kg)
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Patient Satisfaction Clinical Global Impressions Scale (typically either CGI-Severity or CGI-Improvement)
Overall patient satisfaction Clinical Global Impressions (typically either CGI-Severity or CGI-Improvement) rated on a numerical scale. Unit of Measure: Score on a scale Scale Range (Minimum and Maximum Values): 1 to 7 Direction of Scores: Higher scores mean a worse outcome (e.g., greater illness severity or worsening condition).
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Incidence of Adverse Events Related to Intratracheal Analgesia
Number of participants experiencing at least one adverse event related to the intratracheal analgesia technique. Unit of Measure: Number of participants
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Incidence of Serious Adverse Events (SAEs)
Number of participants experiencing a serious adverse event during the study period. Unit of Measure: Number of participants
Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 6 months is below that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Bizet